ElevatION: NET-201 A Phase II Study to Evaluate the Efficacy and Safety of PDR001 in Patients with Metastatic, Well-Differentiated NET of Pancreatic/GI/Thoracic Origin or Poorly-Differentiated GEP NEC Who Have Progressed on Prior Treatment

Beitrag bei einer Tagung


Details zur Publikation

Autor(en): Yao JC, Yao JC, Fazio N, Li D, Pavel ME, Strosberg J, Bergsland E, Ruszniewski P, Voi M, Wu C, Degtyarev E, Degtyarev E, Aimone P, Aimone P, Singh S
Jahr der Veröffentlichung: 2018
Band: 106
Seitenbereich: 218-218
ISSN: 0028-3835


FAU-Autoren / FAU-Herausgeber

Pavel, Marianne Ellen
Medizinische Klinik 1 - Gastroenterologie, Pneumologie und Endokrinologie


Autor(en) der externen Einrichtung(en)
Beaujon Hospital / Hôpital Beaujon
City of Hope Medical Center
European Institute of Oncology / Istituto Europeo di Oncologia (IEO)
H. Lee Moffitt Cancer Center & Research Institute
Novartis AG
Sunnybrook Health Sciences Centre
University of California San Francisco (UCSF)
University of Texas MD Anderson Cancer Center


Zitierweisen

APA:
Yao, J.C., Yao, J.C., Fazio, N., Li, D., Pavel, M.E., Strosberg, J.,... Singh, S. (2018). ElevatION: NET-201 A Phase II Study to Evaluate the Efficacy and Safety of PDR001 in Patients with Metastatic, Well-Differentiated NET of Pancreatic/GI/Thoracic Origin or Poorly-Differentiated GEP NEC Who Have Progressed on Prior Treatment. (pp. 218-218).

MLA:
Yao, J. C., et al. "ElevatION: NET-201 A Phase II Study to Evaluate the Efficacy and Safety of PDR001 in Patients with Metastatic, Well-Differentiated NET of Pancreatic/GI/Thoracic Origin or Poorly-Differentiated GEP NEC Who Have Progressed on Prior Treatment." 2018. 218-218.

BibTeX: 

Zuletzt aktualisiert 2019-24-01 um 08:36